Skip to content
OpenCapital
Get started

Arbutus Biopharma Corporation ABUS Cash & Equivalents

Cash & Equivalents at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
$188.52M+1.5%
Gilead Sciences logo
Gilead SciencesGILD
$7.63B-3.8%
ALN
Alnylam PharmaceuticalsALNY
$1.71B+67.5%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$248.47M+152%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$25.32M-79.8%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
$283.04M-23.1%

Other financials

Income statement

See full
Revenue$179.1M+10,055%
Operating income$168.9M+757%
Net income$169.7M+792%
EPS (diluted)$0.87+769%

Balance sheet

See full
Total debt$631.0K-46.9%
Total equity$260.2M+229%
Total assets$277.2M+137%

Cash flow

See full
Operating cash flow-$8.1M+39.4%
CapEx--100%
Free cash flow-$4.7M+55.0%

Valuation

See full
Market cap$881.02M+34.1%
Enterprise value$857.94M+38.1%
P/E5.5×—
P/S4.6×-98.0×

Profitability

See full
Operating margin81.7%+42.1pp
Net margin84%+43.4pp
FCF margin-281.5%-119pp

Returns & leverage

See full
Return on equity94.7%+65.1pp
Debt / equity0×0.0×
Current ratio54.3×+48.3×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arbutus Biopharma Corporation's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arbutus Biopharma Corporation's cash & equivalents?
Arbutus Biopharma Corporation (ABUS) reported cash & equivalents of $23.71M in Q1 2026.
How has Arbutus Biopharma Corporation's cash & equivalents changed year-over-year?
Arbutus Biopharma Corporation's cash & equivalents decreased by 36.1% year-over-year, from $37.08M to $23.71M.
What is the long-term trend for Arbutus Biopharma Corporation's cash & equivalents?
Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's cash & equivalents has grown at a -19.2% compound annual growth rate (CAGR), from $52.25M to $18.01M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.